Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
24.87
+0.57 (2.35%)
Jan 22, 2026, 3:04 PM EST - Market open
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.14B in the quarter ending September 30, 2025, with 10.39% growth. This brings the company's revenue in the last twelve months to $4.59B, up 3.08% year-over-year. In the year 2024, Elanco Animal Health had annual revenue of $4.44B with 0.50% growth.
Revenue (ttm)
$4.59B
Revenue Growth
+3.08%
P/S Ratio
2.62
Revenue / Employee
$485,820
Employees
9,450
Market Cap
12.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | 3.07B | 4.20M | 0.14% |
| Dec 31, 2018 | 3.07B | 177.80M | 6.15% |
| Dec 31, 2017 | 2.89B | -24.50M | -0.84% |
| Dec 31, 2016 | 2.91B | 4.40M | 0.15% |
| Dec 31, 2015 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 16.78B |
| Viatris | 14.12B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.13B |
| Amneal Pharmaceuticals | 2.93B |
| Neurocrine Biosciences | 2.68B |
| Hims & Hers Health | 2.21B |
| Lantheus Holdings | 1.53B |
ELAN News
- 7 hours ago - Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement - PRNewsWire
- 8 days ago - Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Elanco Animal Health: Innovation-Led Growth Model Plus Credible Deleveraging Path - Seeking Alpha
- 16 days ago - Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 22 days ago - Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PRNewsWire
- 5 weeks ago - Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs - PRNewsWire
- 5 weeks ago - Jim Cramer Praises Elanco Animal Health: 'They've Turned That Company Around' - Benzinga
- 5 weeks ago - Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript - Seeking Alpha